RefBan

Referral Banners

Yashi

Sunday, December 9, 2012

ScienceDaily: Latest Science News

ScienceDaily: Latest Science News


Updated clinical results show experimental agent ibrutinib as highly active in CLL patients

Posted: 08 Dec 2012 09:27 AM PST

Updated results from early phase clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy. The agent, ibrutinib (PCI-32765), is the first drug designed to target Bruton's tyrosine kinase, a protein essential for CLL-cell survival and proliferation.

Blood cancers: Studies assess genetics, modified treatment to improve outcomes, reduce toxicity

Posted: 08 Dec 2012 09:27 AM PST

Research identifying genetic factors that affect survival of patients with blood cancers and evaluating the effectiveness of modified treatment strategies to improve outcomes while reducing toxicity was recently presented.

Researchers develop novel 3-D culture system for inflammatory breast cancer

Posted: 08 Dec 2012 09:27 AM PST

Inflammatory breast cancer is a very rare and aggressive disease. To understand how this type of cancer spreads, it's crucial to characterize the interactions between cancer cells and their 3-D environment. Researchers have developed a novel, 3-D culture system that mimics the environment surrounding these cancer cells. This model could be used to test new anticancer drugs capable of inhibiting the spread of IBC tumors.

No comments:

Yashi

Chitika